Solara Active Pharma Sciences Ltd
NSE:SOLARA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
320.1
822.35
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SOLARA stock under the Base Case scenario is 539.44 INR. Compared to the current market price of 799.35 INR, Solara Active Pharma Sciences Ltd is Overvalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Solara Active Pharma Sciences Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SOLARA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Solara Active Pharma Sciences Ltd
Balance Sheet Decomposition
Solara Active Pharma Sciences Ltd
Current Assets | 7.6B |
Cash & Short-Term Investments | 180.7m |
Receivables | 3.8B |
Other Current Assets | 3.6B |
Non-Current Assets | 15.3B |
Long-Term Investments | 203.8m |
PP&E | 11B |
Intangibles | 4B |
Other Non-Current Assets | 98.7m |
Current Liabilities | 10.5B |
Accounts Payable | 2.8B |
Accrued Liabilities | 19.7m |
Other Current Liabilities | 7.7B |
Non-Current Liabilities | 1.6B |
Long-Term Debt | 973.2m |
Other Non-Current Liabilities | 581.1m |
Earnings Waterfall
Solara Active Pharma Sciences Ltd
Revenue
|
12.2B
INR
|
Cost of Revenue
|
-7.5B
INR
|
Gross Profit
|
4.7B
INR
|
Operating Expenses
|
-6.2B
INR
|
Operating Income
|
-1.5B
INR
|
Other Expenses
|
-3.9B
INR
|
Net Income
|
-5.4B
INR
|
Free Cash Flow Analysis
Solara Active Pharma Sciences Ltd
INR | |
Free Cash Flow | INR |
SOLARA Profitability Score
Profitability Due Diligence
Solara Active Pharma Sciences Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Solara Active Pharma Sciences Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
SOLARA Solvency Score
Solvency Due Diligence
Solara Active Pharma Sciences Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Solara Active Pharma Sciences Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SOLARA Price Targets Summary
Solara Active Pharma Sciences Ltd
According to Wall Street analysts, the average 1-year price target for SOLARA is 577.32 INR with a low forecast of 571.66 INR and a high forecast of 594.3 INR.
Dividends
Current shareholder yield for SOLARA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SOLARA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.
Contact
IPO
Employees
Officers
The intrinsic value of one SOLARA stock under the Base Case scenario is 539.44 INR.
Compared to the current market price of 799.35 INR, Solara Active Pharma Sciences Ltd is Overvalued by 33%.